5 news items
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
CELU
19 Apr 24
to regain compliance with the Nasdaq continued listing standards. Many factors could cause actual results to differ materially from those described
Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024
CELU
18 Apr 24
could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: Celularity's
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
CELU
15 Apr 24
of rising demand for its advanced biomaterial products; among others. Many factors could cause actual results to differ materially from
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
CELU
8 Apr 24
materially from those described in these forward-looking statements, including but not limited to: Celularity's liquidity situation; the volatility
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
CELU
20 Mar 24
neurodegenerative diseases, among others. Many factors could cause actual results to differ materially from those described in these forward-looking statements
- Prev
- 1
- Next